52 Week Range
As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
EU Medicines Agency Says CHMP Recommends Granting Marketing Authorisation For AstraZeneca's Drug Qtrilmet
Ironwood Pharmaceuticals, AstraZeneca Amend Linzess Collaboration In China
Mylan Expands Oncology Portfolio With Launch Of Generic Faslodex Injection
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.
Biotechnology & Drugs
1 Francis Crick Avenue
Independent Non-Executive Chairman of the Board
Chief Executive Officer, Executive Director
Chief Financial Officer, Executive Director
Executive Vice President - Sustainability, Chief Compliance Officer
Executive Vice President - Human Resources
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
AstraZeneca's diabetes drug, Farxiga, has been granted fast track designation by U.S. regulators for the treatment of heart failure, boosting prospects of wider use of the drug and putting it ahead of rivals.
AstraZeneca Plc said on Monday the U.S. Food and Drug Administration (FDA) had granted fast track designation for the development of its diabetes drug Farxiga to reduce the risk of deadly heart attacks in some patients.
AstraZeneca's cancer treatment Imfinzi has been shown to prolong survival in a particularly aggressive type of lung cancer by close to three months, as the British drugmaker holds its ground in a crowded field against rival immunotherapy drugs.
(Corrects Aug. 9 story to show study points to overall survival and not progression free survival in first paragraph)
AstraZeneca Plc said on Friday a late-stage study showed its top-selling drug, Tagrisso, had significantly helped patients with a type of lung cancer live longer.
AstraZeneca Plc said on Wednesday it had received marketing authorization from China's National Medical Products Administration for its top-selling drug, Tagrisso, to treat adults with a form of lung cancer.
AstraZeneca Plc said on Thursday its experimental drug to treat moderate-to-severe lupus met the main goal in a late-stage study, an encouraging sign after it failed to meet its main target in the final stage of another trial last year.
AstraZeneca Plc said on Thursday its experimental drug to treat moderate-to-severe lupus, anifrolumab, met its main goal in a late-stage study.
Prospects for AstraZeneca's respiratory treatments business improved on Wednesday as a three-drug inhaler was shown to ease smoker's lung and U.S. regulators granted its injectable asthma drug Fasenra special status for a rare lung condition.
AstraZeneca said on Wednesday that the U.S. Food and Drug Administration has granted orphan drug status to its severe asthma drug, Fasenra, to treat eosinophilic oesophagitis (EoE).
AstraZeneca Plc said on Tuesday that the U.S. Food and Drug Administration has granted fast track status for the development of its diabetes drug Farxiga to prevent heart and kidney failure in patients with chronic kidney disease (CKD).
AstraZeneca Plc said on Tuesday that the U.S. Food and Drug Administration granted fast track status for the development of its diabetes drug Farxiga to prevent heart and kidney failure in patients with long-term kidney disease.
A combination of AstraZeneca's lung cancer drug Imfinzi and an experimental treatment failed to extend the lives of patients with advanced non-small cell lung cancer (NSCLC) and high levels of gene mutations, the drugmaker said on Wednesday.
AstraZeneca said on Wednesday a combination treatment including its lung cancer drug Imfinzi failed to extend the lives of patients with advanced non-small cell lung cancer (NSCLC) and high levels of gene mutations.
London-listed drugmaker AstraZeneca Plc said on Wednesday its immunotherapy treatment Imfinzi did not meet the main goal of a late-stage study for advanced non-small cell lung cancer.
* Pandora tops STOXX 600 after keeping FY forecast (Recasts, changes comments; Updates to close)
* Sainsbury's among handful of blue-chip gainers (Adds news items, analyst comment, updates to closing prices)
AstraZeneca made strides on Tuesday toward its goal of adding heart failure to the conditions that can be treated by its diabetes drug Farxiga, putting it ahead of a rival medicine from Eli Lilly.
London's FTSE 100 inched higher in early deals on Tuesday, as AstraZeneca advanced after its diabetes drug Farxiga met the main goal of a heart failure study, offsetting a post-earnings drop for miner BHP.
European shares rose for the third straight session on Tuesday, building on a recovery since late last week as British drugmaker AstraZeneca surged on results of a late-stage study.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.